A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma — Stella
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(20 sites)
United States
Johns Hopkins Hospital, Baltimore, Maryland
Dana-Farber Cancer Institute, Boston, Massachusetts
University of Michigan Health, Ann Arbor, Michigan
Stony Brook University Hospital, Stony Brook, New York
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania